glp-1 autoimmune disease Frontiers GLP-1 Drugs Lower Risk of
Description
The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with chronic kidney disease and type 2 diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] [13].Sharpe A, Morley LC, Tang T, et al
At the cellular level, GLP-1 receptor activation appears to reduce the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1)
Many patients who are initially denied coverage later receive approval after additional supporting records are submitted
